VivoSeq
Respiratory

Berylliosis

3

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Berylliosis is an early-stage landscape with 3 programs across 1 company. The most active players are Takeda. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Infliximab

Organon and Co

Phase 2
No programs
Phase 3
No programs
Approved2

Prednisone

Roxane Laboratories

Mesalamine

Takeda

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 3 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)